Founded by Flagship Pioneering in 2020, Empress Therapeutics generates good medicines, fast, by starting with chemistry inside the human body. The Empress Chemilogics platform uses novel insights that connect the lines of code in DNA with drug-like chemistry made in the human body to create first- or best-in-class oral medicines for a broad range of diseases quickly, predictably, and cost-effectively.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/01/23 | $50,000,000 |
Flagship Pioneering | undisclosed |
